Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Pharmacokinetics of CRS3123 in Healthy Adults
NCT06988423Phase 1Completed
- Sponsor
- Crestone, Inc.
- Start
- Apr 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of crs-3123 in Clostridioides difficile infection (CDI) (2 arms), sponsored by Crestone, Inc. Primary endpoints: Area Under the Curve from Time Zero to Last Quantifiable Concentration, Area Under the Curve from Time Zero to Infinity and 1 more. Started Apr 2025; status: completed.
02
Drugs
crs-3123
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT06988423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06988423.